Yu Yong, SVP of Clinical Development at GENELUX Corp ($GNLX), sold shares on the open market three times in the past year for a total of $32,323. His most recent sale occurred on November 17, 2025. These transactions rank 10,756th among 11,678 insiders by sale value, well below the average of $8.6 million across 6.4 transactions per insider. Yu Yong made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 24, 2026 | GENELUX Corp | $GNLX | Yu Yong | SVP, Clinical Development | S | Common Stock | 906 | $2.42 | 144,938.0000 | 38,051,771 | 0.62% | 0.00% |
| Aug. 21, 2025 | GENELUX Corp | $GNLX | Yu Yong | SVP, Clinical Development | S | Common Stock | 3219 | $3.36 | 146,817.0000 | 34,604,296 | 2.15% | 0.01% |
| Nov. 17, 2025 | GENELUX Corp | $GNLX | Yu Yong | SVP, Clinical Development | S | Common Stock | 973 | $5.37 | 145,844.0000 | 38,051,771 | 0.66% | 0.00% |
| Sept. 1, 2025 | GENELUX Corp | $GNLX | Yu Yong | SVP, Clinical Development | D | Stock Option (Right to Buy) | 207652 | $0.00 | 0.0000 | 34,604,296 | 100.00% | 0.60% |
| Sept. 1, 2025 | GENELUX Corp | $GNLX | Yu Yong | SVP, Clinical Development | A | Stock Option (Right to Buy) | 207652 | $0.00 | 207,652.0000 | 34,604,296 | 9999.99% | 0.60% |
| Sept. 1, 2025 | GENELUX Corp | $GNLX | Yu Yong | SVP, Clinical Development | D | Stock Option (Right to Buy) | 65000 | $0.00 | 0.0000 | 34,604,296 | 100.00% | 0.19% |
| Sept. 1, 2025 | GENELUX Corp | $GNLX | Yu Yong | SVP, Clinical Development | A | Stock Option (Right to Buy) | 65000 | $0.00 | 65,000.0000 | 34,604,296 | 9999.99% | 0.19% |
| Aug. 27, 2025 | GENELUX Corp | $GNLX | Yu Yong | SVP, Clinical Development | A | Common Stock | 101480 | $0.00 | 150,036.0000 | 34,604,296 | 209.00% | 0.29% |
| Aug. 27, 2025 | GENELUX Corp | $GNLX | Yu Yong | SVP, Clinical Development | A | Stock Option (Right to Buy) | 134520 | $0.00 | 134,520.0000 | 34,604,296 | 9999.99% | 0.39% |
| May 12, 2025 | GENELUX Corp | $GNLX | Yu Yong | VP, Clinical Trial Operations | S | Common Stock | 5579 | $2.92 | 47,640.0000 | 34,604,296 | 10.48% | 0.02% |
| March 14, 2025 | GENELUX Corp | $GNLX | Yu Yong | VP, Clinical Trial Operations | A | Common Stock | 13350 | $0.00 | 53,219.0000 | 0 | 33.48% | 0.00% |
| Dec. 18, 2024 | GENELUX Corp | $GNLX | Yu Yong | VP, Clinical Trial Operations | A | Stock Option (right to buy) | 39000 | $0.00 | 39,000.0000 | 0 | 9999.99% | 0.00% |
| Dec. 18, 2024 | GENELUX Corp | $GNLX | Yu Yong | VP, Clinical Trial Operations | A | Common Stock | 29000 | $0.00 | 39,869.0000 | 0 | 266.81% | 0.00% |
| June 24, 2024 | GENELUX Corp | $GNLX | Yu Yong | VP, Clinical Trial Operations | S | Common Stock | 6849 | $2.12 | 10,869.0000 | 0 | 38.66% | 0.00% |
| Feb. 19, 2024 | GENELUX Corp | $GNLX | Yu Yong | VP, Clinical Trial Operations | A | Common Stock | 3661 | $0.00 | 6,161.0000 | 0 | 146.44% | 0.00% |
| March 14, 2024 | GENELUX Corp | $GNLX | Yu Yong | VP, Clinical Trial Operations | A | Common Stock | 11557 | $0.00 | 17,718.0000 | 0 | 187.58% | 0.00% |
| May 29, 2024 | GENELUX Corp | $GNLX | Yu Yong | VP, Clinical Trial Operations | P | Common Stock Warrant (Right to Buy) | 2500 | $0.00 | 2,500.0000 | 0 | 9999.99% | 0.00% |
| May 29, 2024 | GENELUX Corp | $GNLX | Yu Yong | VP, Clinical Trial Operations | P | Common Stock | 2500 | $0.00 | 2,500.0000 | 0 | 9999.99% | 0.00% |